Long-term Ocular Safety in Children Treated with Mitogen-Activated Protein Kinase Pathway Inhibitor Therapy
Year: 2025
Type: article
Abstract: The United States Food and Drug Administration has approved five MEK inhibitor (MEKi) agents trametinib, selumetinib, mirdametinib, binimetinib, and cobimetinib for various oncologic conditions. Increasingly, children are receiving MEKi treatment for childhood malignancies, yet their risk of MEKi-related ocular adverse events (OAE) is not well understood.1-3
Source: Ophthalmology
Authors: Robert A. Avery, Andrea M. Gross, Chantal Cousineau-Krieger, Tiarnán D.L. Keenan, Taylor McManus, Connor J. Dallas, Christopher Hampton, Andrea Baldwin, Fangming Jin, Kara Heisey, Kristen Zeller, Grant T. Liu, Chinwe Okeagu, Rachel J. Bishop, Michael J. Fisher, Brigitte C. Widemann, M. Teresa Magone
Language: English
Topic: Drug-Induced Ocular Toxicity
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,990
Funder: National Institutes of Health
OpenAlex ID: W4415015678